RGEN logo

Repligen Stock Price

Symbol: NasdaqGS:RGENMarket Cap: US$6.7bCategory: Pharmaceuticals & Biotech

RGEN Share Price Performance

US$118.91
-43.29 (-26.69%)
33.8% undervalued intrinsic discount
US$179.75
Fair Value
US$118.91
-43.29 (-26.69%)
33.8% undervalued intrinsic discount
US$179.75
Fair Value
Price US$118.91
AnalystConsensusTarget US$179.75

RGEN Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget·Updated
Fair Value US$179.75 33.8% undervalued intrinsic discount

Biomanufacturing Expansion Will Create New Global Opportunities

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative

RGEN Community Fair Values

Recent RGEN News & Updates

No updates

Repligen Corporation Key Details

US$674.0m

Revenue

US$328.3m

Cost of Revenue

US$345.6m

Gross Profit

US$359.5m

Other Expenses

-US$13.8m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-0.25
Gross Margin
51.29%
Net Profit Margin
-2.05%
Debt/Equity Ratio
34.4%

Repligen Corporation Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About RGEN

Founded
1981
Employees
1778
CEO
Olivier Loeillot
WebsiteView website
www.repligen.com

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

U.S. Market Performance

  • 7 Days: -2.7%
  • 3 Months: 10.7%
  • 1 Year: 17.5%
  • Year to Date: 5.9%
In the last week, the market has fallen 2.7%, dragged down most by the Financials. In the last year, the market is actually up 18%. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading